索拉非尼在原发性肝癌治疗中的临床研究进展
Sorafenib in the Treatment of Hepatocellular Carcinoma
DOI: 10.12677/ACM.2020.1010339, PDF,   
作者: 姚 欣, 杨建军*：延安大学附属医院肿瘤介入科，陕西 延安
关键词: 原发性肝癌；HCC；索拉非尼；靶向治疗；免疫治疗；Hepatocellular Carcinoma； HCC； Sorafenib； Targeted Therapy； Immunity Therapy
摘要: 分子靶向治疗在原发性肝癌(hepatocellular carcinoma, HCC)治疗中起重要作用，目前，新型多靶点抗肿瘤药物索拉非尼是关键的靶向治疗药物之一。它具有双重的抗肿瘤作用：既可通过阻断由RAF/MEK/ERK介导的细胞信号传导通路而直接抑制肿瘤细胞的增殖，还可通过抑制VEGFR和血小板衍生生长因子(PDGF)受体而阻断肿瘤新生血管的形成，间接地抑制肿瘤细胞的生长。索拉非尼联合免疫治疗晚期原发性肝癌有一定前景。本文就索拉非尼在原发性肝癌治疗中的相关临床研究进展作一综述。
Abstract: Molecular targeted therapy plays an important role in the treatment of primary liver cancer (hepatocellular carcinoma, HCC). At present, the new multi-target anti-tumor drug sorafenib is one of the key targeted therapy drugs. It has a dual anti-tumor effect: it can directly inhibit the proliferation of tumor cells by blocking the cell signaling pathway mediated by RAF/MEK/ERK, and it can also inhibit VEGFR and platelet-derived growth factor (PDGF) receptors, block the formation of tumor blood vessels and indirectly inhibit the growth of tumor cells. Sorafenib combined with immunotherapy has certain prospects for advanced primary liver cancer. This article reviews the progress of sorafenib in the treatment of primary liver cancer.
文章引用：姚欣, 杨建军. 索拉非尼在原发性肝癌治疗中的临床研究进展[J]. 临床医学进展, 2020, 10(10): 2241-2245. https://doi.org/10.12677/ACM.2020.1010339

参考文献

[1] Khemlina, G., Ikeda, S. and Kurzrock, R. (2017) The Biology of Hepatocellular Carcinoma: Implications for Genomic and Immune Therapies. Molecular Cancer, 16, 149. [Google Scholar] [CrossRef] [PubMed]
[2] Arrese, M., Hernandez, A., Astete, L., Estrada, L., Cabello-Verrugio, C. and Cabrera, D. (2018) TGF-β and Hepatocellular Carcinoma: When a Friend Becomes an Enemy. Current Protein & Peptide Science, 19, 1172-1179. [Google Scholar] [CrossRef] [PubMed]
[3] 夏锋, 李雪松. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(3): 514-518.
[4] Boland, P. and Wu, J. (2018) Systemic Therapy for Hepatocellular Carcinoma: Beyond Sorafenib. Chinese Clinical Oncology, 7, 50. [Google Scholar] [CrossRef] [PubMed]
[5] Li, Z., Gao, J., Zheng, S.M., et al. (2020) The Efficacy of Sorafenib in Preventing Hepatocellular Carcinoma Recurrence after Resection: A Systematic Review and Meta-Analysis. Revista Espanola de Enfermedades Digestivas, 112, 201-210. [Google Scholar] [CrossRef] [PubMed]
[6] Abdelgalil, A.A., Alkahtani, H.M. and Al-Jenoobi, F.I. (2019) Sorafenib. Purchase Profiles of Drug Substances, Excipients, and Related Methodology, 44, 239-266. [Google Scholar] [CrossRef] [PubMed]
[7] Liu, G., Kuang, S., Cao, R., Wang, J., Peng, Q. and Sun, C. (2019) Sorafenib Kills Liver Cancer Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids via the ATP-AMPK-mTOR-SREBP1 Signaling Pathway. The FASEB Journal, 33, 10089-10103. [Google Scholar] [CrossRef] 
[8] Li, X.G., Chen, W.R., Liu, K.H., et al. (2020) Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway. SJPD117913229757, 2020 (Default), 8081-8091. [Google Scholar] [CrossRef] 
[9] Labeur, T.A., Hofsink, Q., Takkenberg, R.B., et al. (2020) The Value of Sorafenib Trough Levels in Patients with Advanced Hepatocellular Carcinoma—A Sub-Study of the SORAMIC Trial. Acta Oncologica, 59, 1028-1035. [Google Scholar] [CrossRef] 
[10] 胡倍源, 覃伟, 董琼珠, 钦伦秀. 肝细胞癌(HCC)对索拉非尼耐药相关机制的研究进展[J]. 复旦学报(医学版), 2018, 45(6): 884-888.
[11] Tang, X., Yang, W., Shu, Z., et al. (2019) MicroRNA-223 Promotes Hepatocellular Carcinoma Cell Resistance to Sorafenib by Targeting FBW7. Oncology Reports, 41, 1231-1237. [Google Scholar] [CrossRef] [PubMed]
[12] 刘国锟, 郭艳霞. 索拉菲尼治疗晚期肝癌患者的临床疗效和安全性分析[J]. 中国处方药, 2020, 18(7): 77-78.
[13] Ai, L., Xu, Z., Yang, B., He, Q. and Luo, P. (2019) Sorafenib-Associated Hand-Foot Skin Reaction: Practical Advice on Diagnosis, Mechanism, Prevention, and Management. Expert Review of Clinical Pharmacology, 12, 1121-1127. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, P., Tan, G., Zhu, M., Li, W., Zhai, B. and Sun, X. (2018) Hand-Foot Skin Reaction Is a Beneficial Indicator of Sorafenib Therapy for Patients with Hepatocellular Carcinoma: A Systemic Review and Meta-Analysis. Expert Review of Gastroenterology & Hepatology, 12, 1-8. [Google Scholar] [CrossRef] [PubMed]
[15] Jiang, Y., Chen, M., Nie, H. and Yuan, Y. (2019) PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics, 15, 1111-1122. [Google Scholar] [CrossRef] [PubMed]
[16] Voutsadakis, I.A. (2019) PD-1 Inhibitors Monotherapy in Hepatocellular Carcinoma: Meta-Analysis and Systematic Review. Hepatobiliary & Pancreatic Diseases International, 18, 505-510. [Google Scholar] [CrossRef] [PubMed]
[17] Ghavimi, S., Apfel, T., Azimi, H., Persaud, A. and Pyrsopoulos, N.T. (2020) Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. Journal of Clinical and Translational Hepatology, 8, 168-176. [Google Scholar] [CrossRef] 
[18] Finkelmeier, F., Waidmann, O. and Trojan, J. (2018) Nivolumab for the Treatment of Hepatocellular Carcinoma. Expert Review of Anticancer Therapy, 18, 1169-1175. [Google Scholar] [CrossRef] [PubMed]
[19] Feng, D., et al. (2017) Initial Experience of Anti-PD1 Therapy with Nivolumab in Advanced Hepatocellular Carcinoma. Oncotarget, 8, 96649-96655. [Google Scholar] [CrossRef] [PubMed]
[20] El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. [Google Scholar] [CrossRef] 

为你推荐